摘要
目的 比较紫杉醇+卡铂与紫杉醇+顺铂治疗NSCLC疗效和毒性。方法 46例初治的NSCLC随机分入紫杉醇+卡铂组(A组)和紫杉醇+顺铂组(B组) ,化疗2周期后进行评价。结果 A组有效率为5 7% ,B组有效率为5 2 % ,二组疗效无显著差异(P >0 0 5 )。胃肠道反应、肾毒性和肌肉关节疼痛A组较B组轻(P <0 0 5 )。结论 紫杉醇+卡铂治疗NSCLC可能会取代紫杉醇+顺铂的联合化疗。
Objective To evaluate and compare the efficacy and toxicity of Paclitaxel plus Carboplatin and Paclitaxel plus Cisplatin in the treatment of advanced non-small cell lung cancer. Methods Forty-six untreated patients with advanced non-small cell lung cancer were randomized into Paclitaxel plus Carboplatin group (group A) and Paclitaxel plus Cisplatin group(group B).Efficacies and toxicities were assessed after 2 cycles of treatment for individual patients.Results The response rate in A group was 57% and in B group was 52%.There was no significant difference of RR between A and B groups(P> 0.05). Gastrointestinal reaction,myalgia or orthralgia and renal dysfunction in group A was higher than those in group B (P<0.05).Conclusions Paclitaxel plus Carboplatin in treatment of advanced non-small cell lung cancer is better than Paclitaxel plus Cisplatin.
出处
《河南肿瘤学杂志》
2005年第2期125-127,共3页
Henan Journal of Oncology
关键词
NSCLC
紫杉醇
卡铂
顺铂
对比
NSCLC
Paclitaxel
Carboplatin
Cisplatin
comparison
